News
-
-
-
-
COMMUNIQUÉ DE PRESSE
MIRA Pharmaceuticals Showcases Significant Progress and Announces Final Phase of Regulatory Work as It Prepares for IND Submission by Year-End
MIRA Pharmaceuticals, a leading pre-clinical-stage company, provides an update on its achievements and scientific advancements, nearing a milestone: IND application submission for Ketamir-2 and regulatory progress for MIRA-55 -
-
-
COMMUNIQUÉ DE PRESSE
MIRA Pharmaceuticals Unveils Ketamir-2's Principal Metabolite: Nor-Ketamir - a Longer-Acting, Brain Penetrating and Selective Compound Acting on the NMDA PCP Receptor
MIRA Pharmaceuticals unveils new preclinical data on innovative drug candidate Ketamir-2's metabolite Nor-Ketamir-2, showcasing enhanced bioavailability and formulation for advanced at-home neurological treatments -
-
-
COMMUNIQUÉ DE PRESSE
MIRA Pharmaceuticals Announces Positive Discovery of Ketamir-2’s Selective NMDA Binding Mechanism of Action
MIRA Pharmaceuticals announced positive preclinical data for novel ketamine analog Ketamir-2, showing selective NMDA inhibition and enhanced safety profile, advancing towards potential IND submission
